Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 2Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Breast Neoplasms 5Polycystic Ovary Syndrome 3Neoplasms 3Prostatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Breast Carcinoma In Situ 2Wilms Tumor 1Venous Thromboembolism 1Tuberous Sclerosis 1Thrombosis 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Perioperative Inflammatory Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Margins of Excision 1Lymphangioleiomyomatosis 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × Simvastatin × Clear all
NCT00281476 2011-11-01

The Effect of High Dose Simvastatine on Multiple Myeloma

Vejle Hospital

Phase 1/2 Completed
10 enrolled
Plasma cell

Multiple Myeloma

NCT00399867 2006-12-20

Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma.

Ludwig-Maximilians - University of Munich

Phase 2 Completed
30 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡